Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000852 · ClinicalTrials.gov registry record · NA

A Pilot Study of Allogeneic Lymphocyte Transfer in HIV Infection

A NA study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT00000852: Completed NA study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00000852 is a NA study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 12 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000852, a NA study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

To examine, in HIV-infected patients, the safety of allogeneic lymphocyte transfer (i.e., infusion of white blood cells taken from an HIV-negative parent, sibling, or adult offspring who has a compatible blood type). To measure the distribution and survival of allogeneic lymphocytes in the circulation of HIV-infected patients, and to determine whether their infusion results in enhanced immunity. To determine whether enhanced immunity is passively transferred or actively induced. There is evidence that periodic infusion of allogeneic lymphocytes obtained from the peripheral blood of HLA-matched HIV-1 seronegative siblings of patients with AIDS can, in some instances, restore the number of circulating CD4+ lymphocytes. However, more controlled studies are needed to better quantitate the immunologic reconstitution seen with this type of therapy.

Conditions Studied

Interventions

  • PROCEDURE Allogeneic lymphocyte transfer

Study Locations (1)

Ohio

  • Univ Hosp of Cleveland / Case Western Reserve Univ - Cleveland

Trial Details

FieldValue
Enrollment Target 12 participants
Phase NA

What the finished NCT00000852 record still lists

NCT00000852 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (97% lower).

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Allogeneic lymphocyte transfer is the first listed.

NCT00000852 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT00000852 about?

NCT00000852 is a clinical study titled "A Pilot Study of Allogeneic Lymphocyte Transfer in HIV Infection". To examine, in HIV-infected patients, the safety of allogeneic lymphocyte transfer (i.e., infusion of white blood cells taken from an HIV-negative parent, sibling, or adult offspring who has a compatible blood type). To measure the distribution and survival of allogeneic lymphocytes in the circulati...

What is the current status of trial NCT00000852?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants.

What conditions does trial NCT00000852 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00000852?

The interventions under investigation include: Allogeneic lymphocyte transfer (PROCEDURE).

Who is sponsoring clinical trial NCT00000852?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000852 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00000852's enrollment target sits among peer trials

12 519th of 542 higher than 18 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Source: ClinicalTrials.gov NCT00000852, the US trial registry maintained by the National Library of Medicine. NCT00000852 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.